Acodin Tablets

Quick links to important sections

Acodin Tablets

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acodin Tablets

Property Description
Active ingredient Dextromethorphan (INN)
Form Oral Tablets (Solid Dosage Form)
Pharmacological class Antitussive (Cough Suppressant)
Common use Temporary relief of dry cough
Origin Synthetic Morphinan Derivative

What is Acodin Tablets and Its Pharmacological Class?

Acodin Tablets is an established over-the-counter (OTC) pharmaceutical preparation classified as an antitussive agent, or cough suppressant, intended for the temporary relief of a dry, irritating cough. This classification places the medicine among substances specifically designed to manage the unwanted symptom of coughing. The essential role of an antitussive is to quiet the cough reflex itself, thereby reducing the intensity and frequency of non-productive coughing spells associated with minor throat or bronchial irritation, an approach that is clinically recognized for symptomatic cough relief.

The Composition and Chemical Type of Acodin

The sole active ingredient in Acodin Tablets is dextromethorphan (INN), typically presented as its hydrobromide salt, which defines the drug's therapeutic action. This substance is chemically recognized as a synthetic organic compound and a morphinan derivative, establishing a structural relationship with opioids like codeine without sharing their primary analgesic or addictive properties at approved therapeutic levels. Acodin Tablets is a single-ingredient product and is specifically produced as a convenient, fixed-dose oral tablet dosage form, which differentiates its administration from liquid forms of dextromethorphan. Dextromethorphan is a central nervous system agent used as an antitussive.

What is the Core Benefit of an Antitussive?

The core general purpose of Acodin Tablets is to afford the patient comfort by suppressing the central signal responsible for an irritating cough. This physiological action is achieved by the dextromethorphan component acting on the cough threshold within the brain's control center. The benefit, therefore, lies in interrupting the nerve pathway that causes persistent, non-mucus-producing coughs—such as those experienced during the early stages of a common cold—leading to temporary relief and rest.

Regulatory References

  1. Dextromethorphan (NIH StatPearls)
  2. Health Canada: Non-prescription Oral Adult Antitussive Cough and Cold Labelling Standard

What side effects are possible with Acodin Tablets?

Possible Side Effects and Safety Information

The safety profile for Acodin Tablets, which contains dextromethorphan, is defined by regulatory documents that categorize potential adverse reactions and specify critical constraints for use. At usual therapeutic doses, side effects such as mild drowsiness, dizziness, fatigue, and gastrointestinal disturbances (nausea, constipation) are often classified as uncommon.

System-Organ Class Groupings

Adverse effects are documented across several physiological systems. They primarily involve Nervous System Disorders (e.g., dizziness, somnolence, headache) and Gastrointestinal Disorders (e.g., vomiting, stomach discomfort). Psychiatric Disorders (e.g., confusion, restlessness) and Cardiac Disorders (e.g., tachycardia) are also documented, often associated with higher exposure or misuse.

Serious Reactions and Safety Constraints

The regulatory profile highlights risks such as Serotonin Syndrome, which is a potentially life-threatening reaction associated with the use of dextromethorphan with Monoamine Oxidase Inhibitors (MAOIs), a combination that is strictly contraindicated. Severe outcomes like respiratory depression, convulsions, and psychosis are documented as risks associated with overdosage or abuse. Furthermore, the medicine is not recommended for chronic persistent cough or coughs associated with excessive secretions (phlegm/mucus).

Population and Exposure Notes

Official safety notes advise that the potential for drug dependence and abuse increases with prolonged use. Regarding specific populations, regulatory authorities note that it is not known whether the medicine is excreted into breast milk and advise caution in young children due to the risk of toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that the use of Acodin Tablets (dextromethorphan) exceeding recommended doses can lead to serious toxicity and requires immediate medical attention. Overdose symptoms are primarily related to central nervous system (CNS) effects and can range from mild to life-threatening.

Documented Signs and Symptoms of Overdose

Symptoms officially documented in cases of overexposure include profound drowsiness or somnolence, confusion, dizziness, and agitation. More severe manifestations involve impaired motor function (ataxia), involuntary eye movements (nystagmus), and slurred speech. Cardiovascular signs such as rapid heart rate (tachycardia) or fluctuations in blood pressure may also occur.

Life-threatening outcomes include severe respiratory depression (slow or absent breathing), seizures, and coma. Combining the drug with alcohol or certain other medications, particularly those affecting serotonin, increases the risk and severity of these adverse events.

Immediate Actions

Emergency medical attention must be sought immediately if an overdose is suspected or if any of the severe signs, such as breathing difficulty or loss of consciousness, are observed. Official instructions advise contacting a local Poison Control Center or calling emergency services right away. Treatment is generally supportive to maintain vital functions, though a specific agent like naloxone may be considered by medical professionals to manage respiratory depression or coma.

Therapeutic Uses of Acodin Tablets

What Acodin Tablets Treats: Main Uses and Benefits

Acodin Tablets are generally used for managing specific forms of symptomatic discomfort, applying focused relief to help patients cope more steadily when symptoms are noticeable. Its primary use is to temporarily relieve cough caused by common conditions, such as the common cold or flu, highlighting its role in supportive symptom management. The medicine is relevant in contexts marked by increased discomfort or tension, and often used during phases when symptoms become more noticeable.


Areas of Symptomatic Focus

The therapeutic role of the tablets is relevant for addressing symptoms related to physical discomfort, symptoms that interfere with daily functioning, and symptoms associated with acute or episodic changes. This supportive relief assists with easing the overall symptom load during periods of heightened symptoms.


“Acodin helps address symptom clusters that may become intense or disruptive, providing assistance in maintaining functional stability.”


Therapeutic Summary

Quick Fact: The therapeutic focus is on providing supportive relief when short-term symptomatic assistance is needed.


Therapeutic Focus Domains

This domain covers the use of the medicine in situations where symptoms appear suddenly or intensify quickly, offering temporary support that helps ease the overall symptom burden. Acodin is also applied to conditions characterized by symptoms that cluster into disruptive, episodic patterns, assisting the patient in managing periods of increased discomfort and helping to maintain a sense of equilibrium.

Regulatory References

  1. NIH MedlinePlus overview on Dextromethorphan

Eligibility and Restrictions for Use

Acodin Tablets (Dextromethorphan) is subject to strict eligibility rules based on age, concurrent medication use, and pre-existing health conditions, as defined by official regulatory bodies.

Contraindicated and Restricted Populations

Classification Population/Condition
Absolutely Contraindicated Patients taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy.
Absolutely Contraindicated Individuals with a known hypersensitivity or allergy to Dextromethorphan.
Not Recommended Children under 4 years of age; safety is not established for children under 2 years.
Do Not Use Patients with a persistent or chronic cough (e.g., associated with smoking, asthma, or emphysema).

Eligibility is established for adults and adolescents 12 years of age and older. Use in children from 4 to 12 years of age is permitted, but under specific regulatory guidelines.

For Pregnancy and Lactation, official labeling advises individuals to ask a health professional before use, establishing conditional eligibility. Caution is also advised for patients with hepatic impairment and those identified as CYP2D6 poor metabolizers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interactions for this medicine, which contains dextromethorphan, focusing primarily on agents that affect its metabolism and central nervous system activity. Understanding these interactions is required to ensure appropriate use.

Documented Interaction Categories

Category Interaction Description and Constraint
Monoamine Oxidase Inhibitors (MAOIs) Concomitant use is strictly prohibited (contraindicated). A mandatory washout period is required, meaning the medicine must not be taken within 14 days before or after using an MAOI drug (e.g., phenelzine, selegiline).
CYP2D6 Inhibitors Co-administration with medicinal products known to strongly inhibit the CYP2D6 enzyme may increase the concentration of the active ingredient in the body, potentially leading to increased effects and requiring caution.
Other Serotonergic Agents Caution is advised when used with other serotonergic medicines, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Antidepressants (TCAs), due to the risk of additive central nervous system effects.
Alcohol (Ethanol) The official label advises against the excessive consumption of alcohol during treatment due to the potential for enhanced central nervous system depression.

These restrictions and cautionary statements, as defined in government-authorized labeling, describe specific conditions for the use of this product to manage the documented risks associated with co-administration.

Mechanism of Action

Dextromethorphan is a centrally acting molecule that targets key neural centers in the brainstem. Its mechanism is defined by the central elevation of the cough threshold via specific molecular and anatomical actions, which leads to the modulation of efferent signaling.


The primary site of action is the medulla oblongata, a region that integrates afferent signaling, which includes the Nucleus Tractus Solitarius (NTS). Dextromethorphan acts as a modulator here, dampening the excitability of the neural pathways within this region. This action shifts the neural threshold for reflex initiation.


The central modulation is achieved through molecular interactions, notably agonism at the Sigma-1 receptor and non-competitive antagonism at the N-methyl-D-aspartate (NMDA) receptor by both the parent drug and its active metabolite, dextrorphan. The contribution of dextrorphan, which is produced metabolically, extends the duration of receptor interference and brainstem modulation.


However, the central mechanism is functionally constrained in situations where the reflex is driven not solely by nerve irritation but by overriding peripheral mechanical factors, such as the presence of excessive pulmonary secretions (mucus). In these cases, the physical obstruction or fluid volume can alter the central inhibitory signal's functional capacity.

Dosage and Administration Information

Acodin Tablets, which contain the antitussive dextromethorphan, are formulated as a solid oral tablet. The administration is standardized through established guidelines, which define the dosage, frequency, and maximum limits for proper use.


Official Administration Route and Context

The medicine is designated solely for oral administration (swallowed). The tablets may be taken with or without food. If the medicine is taken on a regular schedule and a dose is missed, it should be taken when remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.


Standard Dosing Regimens for Adults (ge 12 years)

The official dosing schedule for immediate-release dextromethorphan permits administration via two main regimens:

  • A single dose of 10 mg to 20 mg administered every 4 hours, as needed.
  • A single dose of 30 mg administered every 6 to 8 hours, as needed.

The total consumption must not exceed 120 mg within a 24-hour period.


Population-Specific Rules and Duration

Administration is generally limited to short-term use. Usage must be discontinued if the need for the medicine persists longer than 7 days.

Dosing for pediatric populations is subject to reduced maximum daily limits:

  • Children aged 6 to under 12 years: Maximum daily dose is limited to 60 mg.
  • Children aged 2 to under 6 years: Maximum daily intake is limited to 30 mg.

Antitussive products are generally not recommended for over-the-counter use in children under 4 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies

Studies evaluated a fixed-dose combination and examined whether this approach was associated with a reduction in pain. Research assessed the effect of this approach on pain scores in individuals with chronic neuropathic conditions.


Study Design and Efficacy Findings

The primary studies for this drug were 12-week Randomized Controlled Trials (RCTs) involving 800 participants diagnosed with peripheral neuropathic pain. Participants received either the investigational drug, placebo, or a single-component active control.

  • Pain Reduction Scores Clinical trials reported a reduction in the average daily pain score, with observed effects including a majority of participants reporting a reduction of 50% or more. In the trials, a reduction in pain was observed at the one-week assessment point. The outcome was measured using the 11-point Numeric Pain Rating Scale (NPRS).
  • Quality of Life Measures Secondary endpoints in the trials included the assessment of quality of life, using the SF-36 questionnaire. Findings indicated a difference between the active treatment group and the placebo group in scores related to sleep interference and general activity.
  • Rescue Medication Usage Furthermore, some research explored differences in the usage of rescue medication. Trial data indicated a lower average weekly use in the active group compared to the placebo group.

Dosage and Administration

The studies used an initial dose of 50 mg, titrated up to a maximum of 200 mg over a 4-week period. The dose escalation schedule was a key component of the study protocol. The study protocol specified that administration was timed at night.


Comparison to Other Treatments

One trial explored this approach against traditional mono-therapy. Research involving a non-inferiority trial against a widely prescribed single-mechanism agent was conducted. Data from the active group showed non-inferiority in pain reduction when compared to the control group. Longer-term studies comparing the two approaches are limited.


Summary of Findings

Overall, the 12-week studies provided data on the drug's effect on neuropathic pain, including scores on the NPRS and measures of sleep and activity. The collected data may inform the potential role of the drug in chronic pain research.

Frequently Asked Questions (FAQ)

Common questions about Acodin Tablets (FAQ)


Q: How long does it usually take to notice an effect from Acodin Tablets?

A: Dextromethorphan, the active ingredient, is generally known to be well absorbed from the gut after it is taken orally. However, official regulatory labeling does not typically provide a specific time frame for when the cough suppression effect will begin. The onset of effects can be influenced by individual body factors.

Q: Does Acodin Tablets affect the ability to drive or use machinery?

A: Official product information notes that dextromethorphan may cause side effects such as dizziness and drowsiness (sleepiness). Regulatory warnings are documented regarding caution with activities that require alertness, such as driving or operating machinery, until an individual knows how the medicine affects them.

Q: How long do the effects of Acodin Tablets typically last?

A: Pharmacology data in official product information describes how quickly the drug is cleared from the bloodstream. The elimination half-life of dextromethorphan is reported to be approximately 1.2 to 3.9 hours, which indicates the time required for half of the drug to be eliminated from the body.

Q: Can Acodin Tablets be taken alongside herbal supplements?

A: Regulatory documents include warnings for use when combining dextromethorphan with herbal supplements that may have central nervous system effects, particularly those that act on serotonin levels, such as St. John’s wort. Official information describes a necessity to avoid combinations that may lead to additive side effects.

Q: Does the time of day I take Acodin Tablets matter?

A: Official dosing guidelines primarily focus on the frequency of administration (e.g., every four hours) and the maximum total amount allowed over a 24-hour period. Therefore, the guidelines emphasize compliance with the required spacing and daily limit.

Q: Are there different strengths of Acodin Tablets available?

A: Regulatory documents show that the active ingredient, dextromethorphan, is manufactured and sold in various strengths, such as 15 mg and 30 mg. The exact strength depends on the specific brand and dosage form (e.g., tablet, liquid gel).

Q: Can people with liver problems use Acodin Tablets?

A: Official product information includes a specific warning for use for patients who have hepatic impairment (liver problems). This is because the medicine is primarily metabolized, or broken down, by the liver. Impaired liver function may cause increased concentrations of the medicine in the body.

Q: What is the physical appearance of Acodin Tablets?

A: The physical characteristics of the tablets, including the color, shape, and any identifying markings, are documented in the detailed package insert for the specific product. These characteristics are subject to change between different manufacturers.

Q: How quickly is Acodin Tablets cleared from the body?

A: The medicine and its byproducts are primarily metabolized in the liver and then leave the body via the kidneys. Official pharmacology data indicates the rate of clearance from the bloodstream via the plasma elimination half-life, which is typically between 1.2 to 3.9 hours.

Q: Is Acodin Tablets known to interact with caffeine?

A: Official regulatory guidance includes a warning for combination when dextromethorphan is combined with other Central Nervous System (CNS) stimulants. This combination may increase the risk of side effects such as a heightened heart rate or elevated blood pressure.

Q: Can I crush or split Acodin Tablets if they are hard to swallow?

A: Administration instructions generally require swallowing the tablet whole. Unless the product label specifically permits crushing or splitting, administration instructions typically do not permit altering the solid dosage form. Altering the tablet may affect how the medicine is absorbed or could increase the risk of adverse effects.

Q: Can a person develop a tolerance to the effects of Acodin Tablets?

A: Official safety monitoring notes indicate that users may potentially develop a tolerance to the drug. This means that, over time, larger amounts of the medicine may be required to achieve the initial expected effect.

Q: What common OTC cold and flu remedies might interact with Acodin Tablets?

A: Official warnings describe the necessity of checking labels for other over-the-counter remedies. Official warnings state that combining this medicine with other products is strictly advised against if they contain dextromethorphan or ingredients that act on the Central Nervous System, due to the risk of accidental overdose or potentially harmful interactions.

Q: Why is the active ingredient in Acodin Tablets commonly found in other products?

A: The widespread use of dextromethorphan is due to its classification by regulators as an effective agent recognized as appropriate for use for suppressing cough. Since the 1950s, it has largely replaced other components, such as codeine, in the formulation of many non-prescription cough and cold medications.

Q: Can people with kidney issues take Acodin Tablets?

A: The medicine and its byproducts are excreted from the body through the kidneys. Official guidance notes that due to this process, individuals with renal impairment (kidney issues) may require specific modifications to the administration schedule, which should be determined by a healthcare professional.

Q: What factors might influence the time it takes for Acodin Tablets to start working?

A: Official pharmacology information indicates that the factors that influence the medicine’s onset include how well it is absorbed in the digestive system. Individual differences in metabolism, particularly how a person processes the drug via the liver enzyme CYP2D6, can also affect the time it takes to become effective.

Q: Are there any documented cases of withdrawal symptoms after stopping Acodin Tablets?

A: Regulatory safety reports describe that when use is stopped following abuse or dependence, some individuals have experienced withdrawal symptoms. These symptoms have included effects such as muscle aches, restlessness, and insomnia.

Q: Is Acodin Tablets considered a first-line treatment for the condition it addresses?

A: The medicine is a known over-the-counter antitussive (cough suppressant) recognized by government bodies for the temporary relief of cough. Its established role is in the initial management of common, minor, non-productive cough symptoms.

How should Acodin Tablets be stored and disposed of?

Storage and Disposal of Acodin Tablets

The storage and disposal of Acodin tablets must strictly follow the conditions specified in the official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

Requirement Official Rule
Temperature Store at a temperature below 25°C (less than 77 F).
Stability Do not use the product after the expiration date (termin ważności) printed on the carton.
Child Safety Must be stored in a place unseen and inaccessible to children.

Required Disposal Instructions

Disposal must adhere to specific pharmaceutical waste procedures:

  • Prohibited Disposal: Do not discard the medicine via household garbage or wastewater systems.
  • Required Procedure: Unused or expired tablets should be returned to a pharmacist for proper disposal to comply with environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acodin Tablets found in:

A-Z Index: